Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice! I have May calls which I'm holding for a bit longer... I think the share structure on this one is what makes it so exciting!
La Jolla Pharmaceutical Shares Up 13% Premarket
7:50 AM ET 1/14/20 | Dow Jones
By Michael Dabaie
La Jolla Pharmaceutical Co. (LJPC) shares were up 13%, to $7.90, in premarket trading.
Company director Kevin C. Tang recently acquired about 3 million shares of the company's common stock, according to a filing with the Securities and Exchange Commission.
Write to Michael Dabaie at michael.dabaie@wsj.com
> Dow Jones Newswires
January 14, 2020 07:50 ET (12:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
La Jolla Pharmaceutical Shares Up 13% Premarket
7:50 AM ET 1/14/20 | Dow Jones
By Michael Dabaie
La Jolla Pharmaceutical Co. (LJPC) shares were up 13%, to $7.90, in premarket trading.
Company director Kevin C. Tang recently acquired about 3 million shares of the company's common stock, according to a filing with the Securities and Exchange Commission.
Write to Michael Dabaie at michael.dabaie@wsj.com
> Dow Jones Newswires
January 14, 2020 07:50 ET (12:50 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
$LJPC opened at $7.93 today!
7.67+0.67 (+9.57%)
As of 9:42AM EST.
$LJPC opened at $7.93 today!
7.67+0.67 (+9.57%)
As of 9:42AM EST.
The SS on this one is very nice...it filled the recent gap yesterday and now it looks like it's headed for $7.00 before any resetting. I have May $4.00 calls and I'm hopefully going to hold until the pps get to $11.00
La Jolla Pharm reports prelim Q4 GIAPREZA net sales were $7.2 million, up 71% from the three months ended December 31, 2018
8:01 AM ET 1/9/20 | Briefing.com
Vials of GIAPREZA shipped from distributors to hospitals (hospital demand) grew 74% for the three months ended December 31, 2019 as compared to the three months ended December 31, 2018 and 18% as compared to the three months ended September 30, 2019. For the twelve months ended December 31, 2019, preliminary GIAPREZA net sales were $23.1 million, up 129% from the twelve months ended December 31, 2018. La Jolla announced the commercial availability of GIAPREZA in the U.S. in March 2018.
$LJPC 6.00 + 0.75 (+14.29%) off to the races!
$LJPC 6.00 + 0.75 (+14.29%) off to the races!
$LJPC 5.85 + 0.60 (+11.43%)
yessss!!! This one is a winner!!!
$LJPC 5.85 + 0.60 (+11.43%)
$LJPC 5.85 + 0.60 (+11.43%)
$LJPC 5.85 + 0.60 (+11.43%)
$LJPC FILLING the gap as we speak and showing strength!
Next level of resistance is at about $7.00
$LJPC FILLING the gap as we speak and showing strength!
Next level of resistance is at about $7.00
$LJPC FILLING the gap as we speak and showing strength!
$LJPC moving!
beautiful SS
(in Mar 20 '20 $4 Calls) up 86%
$LJPC started its move
(in Mar 20 '20 $4 Calls) up 86%
$LJPC Last Price $5.55
Today’s Change +0.300 (+5.71%)
Took my first nibble after watching this for 6 years
$EKSO - Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2019 Financial Results; Company Achieves Record Fourth Quarter Revenue
8:00 AM ET 1/10/20 | Dow Jones
Ekso Bionics Reports Preliminary Fourth Quarter and Full Year 2019 Financial Results; Company Achieves Record Fourth Quarter Revenue
RICHMOND, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced preliminary top line financial results for the fourth quarter and fiscal year ended December 31, 2019.
Total revenue for the fourth quarter of 2019 is an estimated $3.7 million, reflecting year-over-year growth of 12.1% compared to total revenue of $3.3 million in the fourth quarter of 2018, and the highest quarterly revenue ever recorded by the Company. Estimated total revenue for the fourth quarter of 2019 includes approximately $3.2 million in medical revenue. The Company also estimates recognized revenue of approximately $0.5 million on shipments of its industrial products in the fourth quarter of 2019.
Total revenue for fiscal year 2019 is estimated to be approximately $13.9 million, compared to $11.3 million in 2018. This reflects estimated year-over-year growth of 23.0%.
Cash on hand at December 31, 2019 was $10.9 million, compared to $7.7 million at December 31, 2018.
"We are very pleased with the record revenue estimated to have been achieved in the fourth quarter of 2019 and remain committed to identifying additional growth opportunities in 2020," said Jack Peurach, President and Chief Executive Officer of Ekso Bionics. "We believe that partnering with network operators is the most efficient way to drive adoption and to make this technology accessible to the most patients as quickly as possible. We are also working to grow our industrial segment by taking steps to engage with a broader mix of companies in additional markets beyond the manufacturing sector, including a variety of construction companies. We remain confident that our technologies in both the medical and industrial segments offer customers, patients and workers a compelling value proposition and have substantial clinical and commercial benefit."
The anticipated results discussed in this press release are based on management's preliminary, unaudited analysis of financial results for the period and year ended December 31, 2019. As of the date of this press release, the Company has not completed its financial statement reporting process for the period ended December 31, 2019, and the Company's independent registered accounting firm has not audited the preliminary financial data discussed in this press release. During the course of the Company's quarter-end closing procedures and review process, the Company may identify items that would require it to make adjustments, which may be material to the information presented above. As a result, the estimates above constitute forward-looking information and are subject to risks and uncertainties, including possible adjustments to preliminary operating results. The Company expects to report complete fourth quarter and full year 2019 financial results during the last week of February 2020.
About Ekso Bionics(R) Ekso Bionics(R) is a leading developer of exoskeleton solutions that amplify human potential by supporting or enhancing strength, endurance and mobility across medical and industrial applications. Founded in 2005, the company continues to build upon its unparalleled expertise to design some of the most cutting-edge, innovative wearable robots available on the market. Ekso Bionics is the only exoskeleton company to offer technologies that range from helping those with paralysis to stand up and walk, to enhancing human capabilities on job sites across the globe. The company is headquartered in the Bay Area and is listed on the Nasdaq Capital Market under the symbol EKSO. For more information, visit: www.eksobionics.com.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, plans or strategy relating to the marketing and adoption and acceptance of the Company's products and potential for adoption of the Company's products by the market, (ii) estimates or projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, changes resulting from the Company's finalization of its financial statements for and as of the period and year ended December 31, 2019, information or new changes in facts or circumstances that may occur prior to the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2019 that are required to be included in such annual report, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at www.eksobionics.com or refer to our Twitter page at @EksoBionics. The Company does not undertake to update these forward-looking statements.
Investor Contact:
David Carey
212-867-1768
investors@eksobionics.com
Media Contact:
Carrie Yamond Mas
917-371-2320
cmas@eksobionics.com
> Dow Jones Newswires
January 10, 2020 08:00 ET (13:00 GMT)
PLEASE READ THE IMPORTANT DISCLOSURES BELOW.
$LJPC
Last Price 5.25
Today's Change + 1.36 (+34.96%)
Day's Range 4.08 - 5.35
Volume 4,884,807
La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA(TM) (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019
8:00 AM ET 1/9/20 | GlobeNewswire
La Jolla Pharmaceutical Company Announces Preliminary GIAPREZA(TM) (Angiotensin II) Net Sales for the Three and Twelve Months Ended December 31, 2019
SAN DIEGO, Jan. 09, 2020 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced preliminary GIAPREZA(TM) (angiotensin II) net sales for the three and twelve months ended December 31, 2019. For the three months ended December 31, 2019, preliminary GIAPREZA net sales were $7.2 million, up 71% from the three months ended December 31, 2018 and up 26% from the three months ended September 30, 2019. Vials of GIAPREZA shipped from distributors to hospitals (hospital demand) grew 74% for the three months ended December 31, 2019 as compared to the three months ended December 31, 2018 and 18% as compared to the three months ended September 30, 2019. For the twelve months ended December 31, 2019, preliminary GIAPREZA net sales were $23.1 million, up 129% from the twelve months ended December 31, 2018. La Jolla announced the commercial availability of GIAPREZA in the U.S. in March 2018.
As of December 31, 2019, La Jolla had approximately $87.8 million in cash and cash equivalents, compared to $104.8 million as of September 30, 2019. Net cash used in operating activities for the three months ended December 31, 2019 was approximately $17.0 million. La Jolla has no debt.
About GIAPREZA
In December 2017, GIAPREZA(TM) (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body's endogenous regulatory peptide that is central to the renin-angiotensin-aldosterone system to increase blood pressure. Prescribing information for GIAPREZA is available at www.giapreza.com. GIAPREZA is marketed by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary.
IMPORTANT SAFETY INFORMATION
Contraindications
None.
Warnings and Precautions
There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.
Adverse Reactions
The most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.
Drug Interactions
Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARB) may reduce response to GIAPREZA.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For additional information, please see Full Prescribing Information for the United States.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life- threatening diseases. In December 2017, GIAPREZA(TM) (angiotensin II) was approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. In August 2019, GIAPREZA was approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. LJPC-0118 (artesunate) is La Jolla's investigational product for the treatment of severe malaria. For more information, please visit www.ljpc.com.
Forward-looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZA(TM) (angiotensin II) sales; cash used in operating activities; regulatory actions relating to La Jolla's products by the U.S. Food and Drug Administration, European Medicines Agency and/or other regulatory authorities; the outcomes of clinical studies of La Jolla's products; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.
Company Contacts
Sandra Vedrick
Senior Director, Investor Relations
La Jolla Pharmaceutical Company
Phone: (858) 207-4264 Ext: 1135
Email: svedrick@ljpc.com
and
Dennis Mulroy
Chief Financial Officer
La Jolla Pharmaceutical Company
Phone: (858) 207-4264 Ext: 1040
Email: dmulroy@ljpc.com
> Dow Jones Newswires
January 09, 2020 08:00 ET (13:00 GMT)
HP Yet Again Rejects Xerox Takeover Offer -- Barrons.com
10:10 AM ET 1/9/20 | Dow Jones
By Eric J. Savitz
HP Inc. once again has rejected the $22-a-share unsolicited takeover bid from Xerox Holdings as too low.
Earlier this week, Xerox (ticker: XRX) announced that it has lined up financing for the cash portion of its offer for the rival printer company, which consists of $17 a share and the remainder in Xerox shares. But HP (HPQ) on Wednesday said its board continues to find the Xerox bid inadequate.
"We reiterate that the HP Board of Directors' focus is on driving sustainable long-term value for HP shareholders," HP CEO Enrique Lores and Chairman Chip Bergh wrote Wednesday in a letter to Xerox CEO John Visentin. "Your letter dated January 6, 2020 regarding financing does not address the key issue -- that Xerox's proposal significantly undervalues HP -- and is not a basis for discussion. The HP Board of Directors remains committed to advancing the best interests of all HP shareholders and to pursuing the most value-creating opportunities."
Xerox initially made the offer to HP in November, and HP has repeatedly rejected it as both too low and too risky given the substantial borrowings Xerox would require to complete the proposed transaction.
The question for Xerox is whether it is prepared to launch a proxy contest for control of the HP board ahead -- or to launch a hostile tender offer.
HP shares were up 0.6% in recent trading, at $21.06, after closing up 1.3% on Wednesday. The S&P 500 was up 0.5% in recent trading.
Write to Eric J. Savitz at eric.savitz@barrons.com
> Dow Jones Newswires
January 09, 2020 10:10 ET (15:10 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
OpenText Buys Carbonite, Inc.
Published: Dec 24, 2019 8:35 a.m. ET
WATERLOO, Ontario, Dec. 24, 2019 (Canada NewsWire via COMTEX) -- OpenTextTM OTEX, +0.62% (OTEX), "The Information Company," announced today that it has completed the closing of the previously announced acquisition of Carbonite, Inc. ("Carbonite"), provider of cloud-based subscription data protection, backup, disaster recovery and endpoint security to small and medium-sized businesses and prosumers.
"I am delighted to announce today the completion of the Carbonite acquisition and warmly welcome Carbonite customers, partners, and employees to OpenText. Combined, we will be able to provide our customers the first end-point platform that offers data protection, endpoint security, intrusion detection and digital forensics - ensuring cyber resiliency and trusted innovation," said Mark J. Barrenechea, OpenText CEO & CTO. "Carbonite brings a world-class channel organization and partners, allowing OpenText to bring EIM to all size customers including SMB to prosumers."
Barrenechea further added, "We have confidence in our ability to integrate, innovate and grow the business. As previously highlighted, we are targeting for Carbonite to be on our operating model by the end of Fiscal 2021, or sooner. We expect strong cloud growth and cash flow expansion from the acquisition."
Preliminary Financial Overview
OpenText expects Carbonite to contribute no material revenue or operating expenses over the holiday season between December 24(th) and 31(st), within the current quarter (Fiscal 2020 Q2). Further financial projections from OpenText, as well as updated target models, will be provided when the company reports its second quarter Fiscal 2020 financial & business results.
Terms of the Acquisition
-- The tender offer for all outstanding Carbonite shares for $23.00 per share in cash is now complete, Carbonite is now a wholly-owned subsidiary of OpenText -- Total purchase price of approximately $1.45 billion, inclusive of Carbonite's cash and debt -- The total purchase price is approximately 2.9x TTM (Trailing Twelve Months) Carbonite GAAP revenues (as of September 30, 2019), inclusive of annualized full-year reported Webroot GAAP revenues, a significant acquisition by Carbonite which closed in March 2019 -- Current Carbonite Reported Annual Recurring Revenues (ARR) of 90% -- Accretive and expected to be on the OpenText operating model by end of Fiscal 2021 or sooner -- Funded with OpenText's existing cash on hand and debt revolver -- Estimated OpenText net leverage ratio at the closing of approximately 2.5x, with an expectation to return to less than 2x net leverage during the next 4-6 quarters
About OpenText
OpenText, The Information CompanyTM, a market leader in Enterprise Information Management software and solutions, enabling companies to manage, leverage, secure and gain insight into their enterprise information, on-premises or in the cloud. For more information about OpenText (nasdaq/tsx:OTEX) visit www.opentext.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release, including statements regarding OpenText's acquisition of Carbonite, OpenText's plans, objectives, expectations and intentions relating to the acquisition, the acquisition's expected contributions to OpenText's results and OpenText's net leverage, the expected size, scope and growth of OpenText's operations and the markets in which it will operate, expected synergies, as well as the expected benefits of the acquisition, impact on future financial performance including in respect of cloud revenues, cloud margins, adjusted EBITDA, and cash flows, may contain words considered forward-looking statements or information under applicable securities laws. These statements are based on OpenText's current expectations, estimates, forecasts and projections about the operating environment, economies and markets in which the company operates. These statements are subject to important assumptions, risks and uncertainties that are difficult to predict, and the actual outcome may be materially different. OpenText's assumptions, although considered reasonable by the company at the date of this press release, may prove to be inaccurate and consequently, its actual results could differ materially from the expectations set out herein. For additional information with respect to risks and other factors, which could occur, see OpenText's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other securities filings with the SEC and other securities regulators. Unless otherwise required by applicable securities laws, OpenText disclaims any intention or obligations to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Copyright ?2019 Open Text. OpenText is a trademark or registered trademark of Open Text. The list of trademarks is not exhaustive of other trademarks. Registered trademarks, product names, company names, brands and service names mentioned herein are the property of Open Text. All rights reserved. For more information, visit: http://www.opentext.com/who-we-are/copyright-information.
Note: All dollar amounts in this press release are in US dollars unless otherwise indicated.
OTEX-MNA
For more information, please contact:
Harry E. BlountSenior Vice President, Investor RelationsOpen Text Corporation415-963-0825investors@opentext.com
Chris PlunkettVice President, Global CommunicationsOpen Text Corporation519-497-0742publicrelations@opentext.com
View original content:http://www.prnewswire.com/news-releases/opentext-buys-carbonite-inc-300979257.html
SOURCE Open Text Corporation
View original content: http://www.newswire.ca/en/releases/archive/December2019/24/c3998.html
SOURCE: Open Text Corporation
SOURCE: Carbonite, Inc.
Copyright (C) 2019 CNW Group. All rights reserved.
still tracking LJPC?
Press Release for Early Warning Report Regarding IBC Advanced Alloys Corp.
10:16 AM ET 12/23/19 | GlobeNewswire
Press Release for Early Warning Report Regarding IBC Advanced Alloys Corp.
FRANKLIN, Ind., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Mark A. Smith of 401 Arvin Road, Franklin, Indiana, USA, 46131-1549, today announced that on December 13, 2019, he acquired ownership and control of 2,104,540 common shares (the "Common Shares") of IBC Advanced Alloys Corp. (the "Company") at a price of C$0.135 per Common Share for an aggregate purchase price of C$284,113. The Common Shares were acquired by Mr. Smith in connection with the Company's private placement of 2,104,540 Common Shares at a price of C$0.135 per Common Share for gross proceeds to the Company of approximately C$284,113 which closed on December 20, 2019 (the "Private Placement").
Prior to acquiring the Common Shares, Mr. Smith owned 7,005,460 Common Shares and 1,547,258 options and warrants (collectively, the "Convertible Securities"), with each Convertible Security entitling the holder to purchase one Common Share. The 7,005,460 Common Shares represented 12.24% of the total number of issued and outstanding Common Shares prior to giving effect to the Private Placement. If all of the Convertible Securities held by Mr. Smith were exercised prior to giving effect to the Private Placement, an aggregate of 8,552,718 Common Shares would have been owned by Mr. Smith, representing approximately 14.94% of the Company's issued and outstanding Common Shares on a partially-diluted basis.
Immediately following the acquisition of the Common Shares and after giving effect to the Private Placement, Mr. Smith owned a total of 9,110,000 Common Shares representing approximately 15.35% of the Company's issued and outstanding Common Shares and 1,547,258 Convertible Securities. Assuming exercise of all of the Convertible Securities held by Mr. Smith, an aggregate of 10,657,258 Common Shares would be owned by Mr. Smith, representing approximately 17.96% of the Company's issued and outstanding Common Shares on a partially-diluted basis.
Mr. Smith acquired the Common Shares for investment purposes. Mr. Smith may from time to time acquire additional securities, dispose of some or all of the existing or additional securities or may continue to hold the securities of the Company.
The Company's head office is located at 401 Arvin Road, Franklin, IN, USA, 46131-1549.
To obtain a copy of the early warning report filed under applicable Canadian securities laws in connection with the transaction hereunder, please see the Company's profile on the SEDAR website www.sedar.com or contact:
Mark A. Smith
401 Arvin Road
Franklin, IN, USA
46131-1549
Telephone: 317-738-2558
> Dow Jones Newswires
December 23, 2019 10:16 ET (15:16 GMT)
Good news!
$DAKT - Daktronics New Billboard Technology Backed by Improved Support
10:00 AM ET 12/17/19 | GlobeNewswire
Daktronics New Billboard Technology Backed by Improved Support
Features added to industry-standard 400-millimeter module
BROOKINGS, S.D., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Daktronics (NASDAQ-DAKT) of Brookings, South Dakota, announces the DB-6500, the latest addition to their DB-6000 LED digital billboard series. The Out of Home industry-standard 400 by 400-millimeter module features neighborhood-friendly emissions standards, a 10-year brightness guarantee, 12-year parts support and diagnostic information through System Health.
This latest series builds on the most reliable OOH digital billboard to date, Daktronics-backed lifetime image quality, and a host of features that simplify operator experience, now and in the future.
"Sourcing, design and development of the most reliable LED display technology has always been our core focus," said Collin Huber, Daktronics OOH sales manager. "Our latest digital billboard offering outfits display owners with the tested and proven technology to make them successful, with options to complement their various business models, while maintaining good relationships within communities."
Every Daktronics DB-6500 produces directional illumination, producing light out and downward, limiting light toward unintended areas like adjacent neighborhoods. When the situation calls for it, Daktronics even offers site-specific light emissions analysis to determine the brightness of the billboard both horizontally and vertically.
Guaranteed quality
The Daktronics DB-6500 comes with a brightness guarantee, so even after 10 years the display will shine at 5,000 nits. The company's confidence in the quality of its products is also evident in the 12-year parts guarantee.
"Most digital displays can look good for the first few years of consistent use," says Huber, "but at Daktronics, we believe every display should look good for its life. We vet our suppliers very carefully, so we can guarantee access to replacement parts during the billboard's life, providing consistency in brightness and color quality."
Daktronics uses fully sealed components, multiple calibration methods to ensure color consistency and features a factory-installed, integrated SmartLink(TM) controller for redundant communication paths and remote power. Daktronics also tests every component in a state-of-the-art product reliability lab with a thorough, multi-step process.
Diagnostic information
Another option for billboard operators is System Health, an annual subscription that provides diagnostic information about every part of the display hardware from the modules to the computers. It works with any scheduling software and provides diagnostics through one convenient, user-friendly platform called Venus(R) Control Suite.
Huber says it goes beyond the technology in the OOH market. "We understand that choosing a reliable technology partner is part of the upfront decision, and our engineers and reliability experts have that covered. But Daktronics also has OOH experts that can help with everything from permitting and legislation to ad sales strategies and scheduling."
To learn more about the DB-6500 and all the Daktronics LED billboards at www.daktronics.com/OOH.
About Daktronics
Daktronics helps its customers to impact their audiences throughout the world with large-format LED video displays, message displays, scoreboards, digital billboards, audio systems and control systems in sport, business and transportation applications. Founded in 1968 as a USA-based manufacturing company, Daktronics has grown into the world leader in audiovisual systems and implementation with offices around the globe. Discover more at www.daktronics.com.
SAFE HARBOR STATEMENT
Cautionary Notice: In addition to statements of historical fact, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and is intended to enjoy the protection of that Act. These forward-looking statements reflect the Company's expectations or beliefs concerning future events. The Company cautions that these and similar statements involve risk and uncertainties which could cause actual results to differ materially from our expectations, including, but not limited to, changes in economic and market conditions, management of growth, timing and magnitude of future contracts, fluctuations in margins, the introduction of new products and technology, the impact of adverse weather conditions and other risks noted in the Company's SEC filings, including its Annual Report on Form 10-K for its 2019 fiscal year. Forward-looking statements are made in the context of information available as of the date stated. The Company undertakes no obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur.
MEDIA RELATIONS
Joni Schmeichel
OOH Marketing
Tel 605-691-3639
Email Joni.Schmeichel@daktronics.com
> Dow Jones Newswires
December 17, 2019 10:00 ET (15:00 GMT)
You've been here a while...
How many competitors are in this sector?
I saw a video (need to find it) from the BBC touting an Israeli company made exoskeleton.
YouTube alone is filled with exoskeleton prototypes vids etc.
What sets this apart from the rest?
Tx!
$FONR Shareholder Equity
Shares Outstanding 6.4 M
Institutional Ownership 49.97%
Number of Floating Shares 6.2 M
Short Interest as % of Float 0.17%
May actually kiss $40 by Q1 2020 with this SS
Shareholder Equity
Shares Outstanding 53.5 M
Institutional Ownership 96.79%
Number of Floating Shares 44.1 M
Short Interest as % of Float 32.92%
Carl Icahn Bought HP Stake Knowing of Xerox Bid Plans, Fund Says
Bloomberg
Chris Dolmetsch,Bloomberg•December 14, 2019
(Bloomberg) -- A Xerox Holdings Corp. shareholder sued Carl Icahn and an investment vehicle he controls, alleging they bought $1.2 billion worth of HP Inc. shares knowing that Xerox was considering acquiring the stock at a premium.
The Miami Firefighters Relief and Pension Fund filed the lawsuit in New York state court in Manhattan on Friday, alleging Icahn, Icahn Capital LP and High River Limited Partnership breached their fiduciary duties to Xerox by buying HP stock with the knowledge that “Xerox was either considering making an offer to purchase HP, had already approached HP about a possible merger into or acquisition by Xerox, or of the obvious merits of Xerox’s potential acquisition of HP.”
A representative for Icahn was not immediately available for comment.
Icahn Capital is Xerox’s largest shareholder, owning almost 11% of the stock as of September 30. Icahn late that month disclosed that Icahn Capital and High River together owned more than 62.9 million shares of HP, making Icahn the fifth-largest shareholder in the company.
A previous disclosure by Icahn in August listed no HP stock as of June 30. While the date of Icahn’s purchases were not revealed, an analyst speculated two days after the end of the third quarter that an activist investor might be targeting HP shares citing reasons including a “huge spike” in trading volume without an obvious reason, according to the suit.
HP last month rejected an unsolicited, cash-and-stock offer from Xerox worth $22 per share, or about $33 billion. Icahn earlier this month urged HP to push ahead with takeover talks, arguing the hardware maker’s standalone plans amount “to little more than rearranging the deck chairs on the Titanic.” Xerox has taken its case directly to shareholders, saying the takeover would create as much as $1.5 billion in potential revenue growth, according a presentation to investors made public earlier this week.
Read More: Icahn Urges HP to Move Forward With Xerox Merger Discussions
(Updates with details from complaint.)
--With assistance from Scott Deveau.
To contact the reporter on this story: Chris Dolmetsch in Federal Court in Manhattan at cdolmetsch@bloomberg.net
To contact the editors responsible for this story: David Glovin at dglovin@bloomberg.net, Anthony Lin
For more articles like this, please visit us at bloomberg.com
©2019 Bloomberg L.P.
I would check some far out HPQ calls as well
I would check some far out HPQ calls as well
I got a few just in case
$CCC - Clarivate Analytics plc announces secondary offering of ordinary shares
4:40 PM ET 12/2/19 | Dow Jones
LONDON and PHILADELPHIA, Dec. 2, 2019 /CNW/ -- Clarivate Analytics Plc (NYSE:CCC; CCC.WS) (the "Company"), a global leader in providing trusted insights and analytics to accelerate the pace of innovation, announced today that affiliated shareholders of Onex Corporation and Baring Private Equity Asia Group Ltd (BPEA), together with certain other shareholders, intend to offer an aggregate 36 million of the Company's ordinary shares in an underwritten public offering. The selling shareholders have granted the underwriters an option to purchase up to 5.4 million additional ordinary shares. The Company will not receive any of the proceeds from the sale of its ordinary shares by the selling shareholders.
Citigroup Global Markets Inc. and Goldman Sachs are acting as joint book-running managers for the offering.
The Company has filed a registration statement on Form F-1 (including a prospectus) with the Securities and Exchange Commission ("SEC") but said registration statement has not yet become effective. The ordinary shares may not be sold nor any offer to buy be accepted prior to the time the registration statement becomes effective. The filing is available for free on the Company's website (http://ir.clarivate.com) and www.sec.gov. You can also request a copy of this document by contacting Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (800) 831-9146 or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, email: Prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any offer of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Clarivate Analytics
Clarivate Analytics(TM) is a global leader in providing trusted insights and analytics to accelerate the pace of innovation. We have built some of the most trusted brands across the innovation lifecycle, including Web of Science(TM), Cortellis(TM), Derwent(TM), CompuMark(TM), MarkMonitor(TM) and Techstreet(TM). Today, Clarivate Analytics is on a bold entrepreneurial mission to help customers reduce the time from new ideas to life-changing innovations. For more information, please visit clarivate.com.
Forward-Looking Statements
This press release and oral statements included herein may contain forward-looking statements regarding Clarivate Analytics. Forward-looking statements provide Clarivate Analytics' current expectations or forecasts of future events and may include statements regarding results, anticipated synergies and other future expectations. These statements involve risks and uncertainties including factors outside of Clarivate Analytics' control that may cause actual results to differ materially. Clarivate Analytics undertakes no obligation to update or revise the statements made herein, whether as a result of new information, future events or otherwise
Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.
View original content to download multimedia:http://www.prnewswire.com/news-releases/clarivate-analytics-plc-announces-secondary-offering-of-ordinary-shares-300967705.html
SOURCE Clarivate Analytics
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2019/02/c8341.html
/CONTACT:
Media Contact, Tabita Seagrave, Head of Communications, media.enquiries@clarivate.com; Investor Relations Contact, Anthony Gerstein, Head of Investor Relations, anthony.gerstein@clarivate.com, http://clarivate.com
Copyright CNW Group 2019
> Dow Jones Newswires
December 02, 2019 16:40 ET (21:40 GMT)
$PLUG - Plug Power Inc. Announces Proposed Public Offering of Common Stock
5:07 PM ET 12/2/19 | GlobeNewswire
Related Quotes
4:00 PM ET 12/2/19
Symbol Last % Chg
PLUG
3.80 0.00%
Real time quote.
Plug Power Inc. Announces Proposed Public Offering of Common Stock
LATHAM, N.Y., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a leader in providing clean, reliable energy solutions, today announced that it has commenced an underwritten public offering of 40 million shares of its common stock. In addition, Plug Power intends to grant the underwriters a 30-day option to purchase up to an additional 6 million shares of its common stock.
Morgan Stanley and Barclays are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Plug Power intends to use the net proceeds from the offering for working capital and other general corporate purposes, including capital expenditures.
The securities described are being offered by Plug Power pursuant to an automatic shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (the "SEC") and declared effective by the SEC. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained by contacting Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; and Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Plug Power Inc.
The architect of modern hydrogen and fuel cell technology, Plug Power is the innovator that has taken hydrogen and fuel cell technology from concept to commercialization. Plug Power has revolutionized the material handling industry with its full-service GenKey solution, which is designed to increase productivity, lower operating costs and reduce carbon footprints in a reliable, cost-effective way. Plug Power's GenKey solution couples together all the necessary elements to power, fuel and serve a customer. With proven hydrogen and fuel cell products, Plug Power replaces lead acid batteries to power electric industrial vehicles, such as the lift trucks customers use in their distribution centers. Extending its reach into the on-road electric vehicle market, Plug Power's ProGen platform of modular fuel cell engines empowers OEMs and system integrators to rapidly adopt hydrogen fuel cell technology. ProGen engines are proven today, with thousands in service, supporting some of the most rugged operations in the world. Plug Power is the partner that customers trust to take their businesses into the future.
Plug Power Inc. Safe Harbor Statement
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Plug Power Inc. (the "Company"), including, but not limited to, the risks and uncertainties related to market conditions, the expected use of proceeds, and the consummation of the proposed public offering on the terms and conditions described herein or at all. You are cautioned that such statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times that, or by which, such performance or results will have been achieved. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements, including those risks and uncertainties referenced in our public filings with the SEC. For additional disclosure regarding risks and uncertainties faced by the Company, see disclosures contained in the Company's public filings with the SEC including, the "Risk Factors" section of the Annual Report on Form 10-K for the year ended December 31, 2018, and in the prospectus supplement related to the offering. You should consider these factors in evaluating the forward-looking statements included in this presentation and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and the Company undertakes no obligation to update such statements as a result of new information.
Media & Investor Relations Contact:
Teal Vivacqua
Plug Power Inc.
Phone: (518) 738-0269
media@plugpower.com
> Dow Jones Newswires
December 02, 2019 17:07 ET (22:07 GMT)
Long time no speak bro...gotta reach you through the free chat LOL
Hope you still had this one!
WEEEEEEEEEEEEEEEEE!!!!